J0741 Injection Reimbursement & Policy (HCPCS) | OpenPayer

Summary & Overview

HCPCS J0741: Injection of Cabotegravir and Rilpivirine, 2mg/3mg

HCPCS Level II code J0741 denotes the unit for injection of cabotegravir and rilpivirine (2mg/3mg), a long-acting two-drug antiretroviral therapy administered intramuscularly. The code is important nationally as it describes billing for a specialty injectable medication used in HIV treatment regimens designed to improve adherence and reduce dosing frequency. Payers and providers use this HCPCS Level II code to report and reimburse the drug component of the injection separate from administration.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0741 represents, payer coverage considerations, typical sites of service, and the clinical context for use. The publication outlines benchmarks and reimbursement context where available, summarizes relevant policy developments affecting coverage of long-acting injectable antiretrovirals, and provides billing considerations tied to service lines. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0741HCPCS Level IIcabotegravirrilpivirinelong-acting injectableantiretroviral therapyHIV treatmentinjection billingoutpatient infusion

Billing Code Overview

HCPCS Level II code J0741 represents the medication injection of cabotegravir and rilpivirine, 2mg/3mg. This code covers the administration unit for the long-acting, two-drug antiretroviral formulation delivered as an intramuscular injection.

Service type: Medication injection (long-acting antiretroviral therapy)
Typical site of service: Outpatient clinic or physician office, specialty infusion center, or other ambulatory care setting where intramuscular injections are administered

Clinical & Coding Specifications

Clinical Context

A 34-year-old patient with well-controlled HIV-1 infection presents to an outpatient infusion clinic for a scheduled long-acting intramuscular maintenance dose of cabotegravir and rilpivirine. The patient transitioned from daily oral antiretroviral therapy to the injectable regimen after completing the recommended oral lead-in or receiving an initial loading injection series. The clinical workflow includes medication verification and consent, assessment of recent viral load and adherence history, screening for injection site contraindications, documentation of lot numbers and expiration dates, preparation of the combination product J0741, administration as one or two deep intragluteal intramuscular injections per product instructions, observation for immediate adverse reactions for the recommended period, and post-injection counseling. Typical sites of service include outpatient infusion centers, ambulatory clinics, and physician offices with capability for intramuscular injection and observation. Common clinical considerations include ensuring HIV-1 RNA is suppressed before maintenance dosing, monitoring for injection site reactions, and coordinating follow-up dosing appointments.

Coding Specifications

Modifier	Description	When to Use
`00`	Unspecified	Rarely used; not typically applied to drug administration codes but present in modifier list for payer-specific rules

HCPCS J0710: Injection, Cephapirin Sodium, Up to 1 gm

HCPCS-J0600-EDETATE-CALCIUM-DISODIUM-INJECTION-UP-TO-1000-MG

HCPCS J0600: Injection, Edetate Calcium Disodium, Up to 1000 mg

HCPCS-J0696-CEFTRIAXONE-250MG-INJECTION

HCPCS J0696: Injection, ceftriaxone sodium, per 250 mg

HCPCS-J2470-PANTOPRAZOLE-40MG-INJECTION

HCPCS J2470: Injection, Pantoprazole Sodium 40 mg

HCPCS-J0120-INJECTION-TETRACYCLINE-250MG

HCPCS J0120: Injection, Tetracycline, Up to 250 mg

HCPCS-J2150-MANNITOL-25PCT-50ML-INJECTION

HCPCS Level II J2150: Injection, Mannitol 25% in 50 mL

HCPCS-J7610-ALBUTEROL-INHALATION-SOLUTION-COMPOUNDED-DME

HCPCS J7610: Albuterol Inhalation Solution, Compounded, DME

HCPCS-J7622-BECLOMETHASONE-INHALATION-SOLUTION-UNIT-DOSE

HCPCS J7622: Beclomethasone Inhalation Solution, Compounded Unit Dose

HCPCS-J1747-SPESOLIMAB-INJECTION-1MG

HCPCS Level II J1747: Injection, spesolimab-sbzo, 1 mg

HCPCS-J2765-METOCLOPRAMIDE-INJECTION-UP-TO-10-MG

HCPCS J2765: Metoclopramide Injection, Up to 10 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`364A00000X`	Infectious Disease Physician	Specialty managing complex HIV care and overseeing injectable antiretroviral therapy
`207RG0100X`	Internal Medicine	Primary care clinicians who manage long-term HIV therapy and coordinate injections
`363L00000X`	HIV/AIDS Specialist	Clinicians focused on HIV care delivering or supervising long-acting ART
`177PA0000X`	Physician Assistant	Common provider delivering intramuscular injections in outpatient settings
`163W00000X`	Nurse Practitioner	Advanced practice clinicians who frequently administer and manage injectable ART

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B20`	Human immunodeficiency virus [HIV] disease	Primary diagnosis indicating HIV infection; long-acting cabotegravir and rilpivirine is indicated for maintenance therapy in virologically suppressed adults with HIV-1
`Z21`	Asymptomatic human immunodeficiency virus [HIV] infection status	Used for patients with HIV who are currently asymptomatic but require ongoing antiretroviral therapy management
`R22.9`	Local swelling, unspecified	Relevant for reporting significant post-injection swelling at the injection site when documented
`T88.1`	Other complications following immunization, not elsewhere classified	Used if the patient experiences a documented adverse reaction to the injection requiring additional care
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing chronic medication therapy such as long-acting antiretroviral treatment

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly billed for the intramuscular administration of approved medications when payers require a CPT administration code in addition to drug HCPCS
`96361`	Hydration, each additional hour (for use with main hydration code)	Not typically used for this drug; listed only if prolonged observation with intravenous hydration is required for adverse reaction management
`99070`	Supplies and materials (excepting those usually included with the office visit)	Used to bill expendable supplies associated with administration (e.g., syringes, gloves) when allowed by payer
`99406`	Smoking and tobacco-use cessation counseling visit, intermediate	Example of ancillary counseling code that may be performed during the visit when clinically indicated (billing depends on visit documentation)
`G0123`	Screening for unspecified conditions (example CMS G-code)	Facility-specific observation or monitoring codes may be used per payer rules during the post-injection observation period

Note: If a payer requires specific administration CPT codes in addition to the HCPCS drug code J0741, 96372 is the most directly applicable for intramuscular injection administration in outpatient settings.

OpenPayer